Table 5 Priorities stratified by stakeholder role
From: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis
Variable | Aggregate | Clinicians | Policy Makers | Advocates | Chi-squared p-value |
|---|---|---|---|---|---|
| Â | Coef ( SE ) | Coef ( SE ) | Coef ( SE ) | Coef ( SE ) | Â |
Monitoring at-risk populations | 13.75*** | 14.76*** | 14.58*** | 8.33* | 0.28 |
| Â | (1.5) | (2.0) | (2.6) | (3.6) | Â |
Risk Assessment | 5.42*** | 5.73** | 2.92 | 8.33* | 0.47 |
| Â | (1.3) | (1.6) | (2.7) | (3.6) | Â |
Access to treatments | 5.21*** | 4.34* | 6.25* | 6.94 | 0.76 |
| Â | (1.4) | (1.7) | (3.6) | (3.6) | Â |
National guidelines | 8.96*** | 9.55*** | 7.08* | 9.72** | 0.79 |
| Â | (1.4) | (1.7) | (3.3) | (3.6) | Â |
Research infrastructure | 3.96** | 5.03** | −1.25 | 8.33* | 0.08 |
| Â | (1.4) | (1.6) | (2.9) | (3.3) | Â |
Centers of excellence | 6.86*** | 7.81*** | 4.58 | 6.94 | 0.66 |
| Â | (1.5) | (1.9) | (3.0) | (3.9) | Â |
Multidisciplinary management | 8.33*** | 9.20*** | 7.92** | 5.56 | 0.52 |
| Â | (1.4) | (2.0) | (2.3) | (2.5) | Â |
Clinician education | 11.04*** | 11.28*** | 8.75** | 13.89*** | 0.35 |
| Â | (1.3) | (1.9) | (2.4) | (2.5) | Â |
Public awareness | 8.13*** | 9.20*** | 3.75 | 11.11** | 0.15 |
| Â | (1.4) | (1.8) | (2.5) | (3.8) | Â |
Transplantation infrastructure | 0.42 | 1.56 | −2.92 | 1.39 | 0.47 |
| Â | (1.5) | (2.1) | (3.1) | (3.6) | Â |
Measuring social burden | 5.21*** | 3.3 | 8.75** | 6.94 | 0.25 |
| Â | (1.4) | (1.6) | (3.0) | (4.8) | Â |